-
1
-
-
84867316537
-
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
-
COI: 1:CAS:528:DC%2BC38XhsFaksLbP, PID: 22904298
-
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.
-
(2012)
Blood.
, vol.120
, pp. 2843-2852
-
-
Ott, C.J.1
Kopp, N.2
Bird, L.3
Paranal, R.M.4
Qi, J.5
Bowman, T.6
-
2
-
-
84865222098
-
Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition
-
COI: 1:CAS:528:DC%2BC38Xht1Wrs7jK, PID: 22645123
-
Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012;287:28840–51.
-
(2012)
J Biol Chem.
, vol.287
, pp. 28840-28851
-
-
Zhang, G.1
Liu, R.2
Zhong, Y.3
Plotnikov, A.N.4
Zhang, W.5
Zeng, L.6
-
3
-
-
84874720284
-
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
-
Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). Oncotarget. 2012;1588–99.
-
(2012)
Oncotarget
, pp. 1588-1599
-
-
Herrmann, H.1
Blatt, K.2
Shi, J.3
Gleixner, K.V.4
Cerny-Reiterer, S.5
Müllauer, L.6
-
4
-
-
84877097843
-
Inhibition of BET bromodomain targets genetically diverse glioblastoma
-
COI: 1:CAS:528:DC%2BC3sXlsVCmsLo%3D, PID: 23403638
-
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013;19:1748–59.
-
(2013)
Clin Cancer Res.
, vol.19
, pp. 1748-1759
-
-
Cheng, Z.1
Gong, Y.2
Ma, Y.3
Lu, K.4
Lu, X.5
Pierce, L.A.6
-
5
-
-
84888106365
-
Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC3sXhslyku7rF, PID: 24045185
-
Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, et al. Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2013;19:6183–92.
-
(2013)
Clin Cancer Res.
, vol.19
, pp. 6183-6192
-
-
Shimamura, T.1
Chen, Z.2
Soucheray, M.3
Carretero, J.4
Kikuchi, E.5
Tchaicha, J.H.6
-
6
-
-
84927588026
-
Development of the BET bromodomain inhibitor OTX015 (abstract no. C244)
-
Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H, Daibata M. Development of the BET bromodomain inhibitor OTX015 (abstract no. C244). Mol Cancer Ther. 2013;12:C244.
-
(2013)
Mol Cancer Ther.
, vol.12
, pp. C244
-
-
Noel, J.K.1
Iwata, K.2
Ooike, S.3
Sugahara, K.4
Nakamura, H.5
Daibata, M.6
-
7
-
-
78650847770
-
Selective inhibition of BET bromodomains
-
COI: 1:CAS:528:DC%2BC3MXotlGmtA%3D%3D, PID: 20871596
-
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73.
-
(2010)
Nature.
, vol.468
, pp. 1067-1073
-
-
Filippakopoulos, P.1
Qi, J.2
Picaud, S.3
Shen, Y.4
Smith, W.B.5
Fedorov, O.6
-
8
-
-
80053651202
-
Targeting MYC dependence in cancer by inhibiting BET bromodomains
-
COI: 1:CAS:528:DC%2BC3MXhtlWksrnL, PID: 21949397
-
Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci. 2011;108:16669–74.
-
(2011)
Proc Natl Acad Sci.
, vol.108
, pp. 16669-16674
-
-
Mertz, J.A.1
Conery, A.R.2
Bryant, B.M.3
Sandy, P.4
Balasubramanian, S.5
Mele, D.A.6
-
9
-
-
85018175161
-
OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma (abstract no. 5531)
-
Todaro M, Boi M, Vurchio V, Ercole E, Machiorlatti R, Messana K, et al. OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma (abstract no. 5531). Cancer Res. 2014;74:5531.
-
(2014)
Cancer Res
, vol.74
, pp. 5531
-
-
Todaro, M.1
Boi, M.2
Vurchio, V.3
Ercole, E.4
Machiorlatti, R.5
Messana, K.6
-
10
-
-
84925375324
-
The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs
-
COI: 1:CAS:528:DC%2BC2MXmtVahsbc%3D, PID: 25623213
-
Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21:1628–38.
-
(2015)
Clin Cancer Res.
, vol.21
, pp. 1628-1638
-
-
Boi, M.1
Gaudio, E.2
Bonetti, P.3
Kwee, I.4
Bernasconi, E.5
Tarantelli, C.6
-
11
-
-
0019487152
-
History of pharmacokinetics
-
COI: 1:CAS:528:DyaL3MXktFOkt7w%3D, PID: 7025032
-
Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12:537–62.
-
(1981)
Pharmacol Ther.
, vol.12
, pp. 537-562
-
-
Wagner, J.G.1
-
12
-
-
0030064911
-
The use of population pharmacokinetics in drug development
-
COI: 1:STN:280:DyaK2s%2FmtlShtw%3D%3D, PID: 8906893
-
Vozeh S, Steimer J-L, Rowland M, Morselli P, Mentré F, Balant L, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet. 1996;30:81–93.
-
(1996)
Clin Pharmacokinet.
, vol.30
, pp. 81-93
-
-
Vozeh, S.1
Steimer, J.-L.2
Rowland, M.3
Morselli, P.4
Mentré, F.5
Balant, L.6
-
13
-
-
84933040610
-
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
-
COI: 1:CAS:528:DC%2BC2cXhsVCrtbbO, PID: 25174395
-
Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A, et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015;34:3357–68.
-
(2015)
Oncogene
, vol.34
, pp. 3357-3368
-
-
Althoff, K.1
Beckers, A.2
Bell, E.3
Nortmeyer, M.4
Thor, T.5
Sprussel, A.6
-
14
-
-
84908086741
-
Development and validation of an UPLC–MS/MS method for quantitative analysis of OTX015 in human plasma samples
-
COI: 1:CAS:528:DC%2BC2cXhslekt7vM
-
Odore E, Lokiec F, Weill S, Noel JK, Herait P, Bekradda M, et al. Development and validation of an UPLC–MS/MS method for quantitative analysis of OTX015 in human plasma samples. Anal Methods. 2014;6:9108–15.
-
(2014)
Anal Methods.
, vol.6
, pp. 9108-9115
-
-
Odore, E.1
Lokiec, F.2
Weill, S.3
Noel, J.K.4
Herait, P.5
Bekradda, M.6
-
15
-
-
19044400906
-
Maximum likelihood estimation in nonlinear mixed effects models
-
Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–38.
-
(2005)
Comput Stat Data Anal.
, vol.49
, pp. 1020-1038
-
-
Kuhn, E.1
Lavielle, M.2
-
16
-
-
0037115430
-
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
-
PID: 12488418
-
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.
-
(2002)
J Clin Oncol.
, vol.20
, pp. 4713-4721
-
-
Friberg, L.E.1
Henningsson, A.2
Maas, H.3
Nguyen, L.4
Karlsson, M.O.5
-
18
-
-
84959155506
-
-
Odore E, Rezai K, Riveiro E, Bourdel F, Herait P, Cvitkovic E, et al. A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies (abstract no. LB-231). Cancer Res. 2014;74:LB-231
-
Odore E, Rezai K, Riveiro E, Bourdel F, Herait P, Cvitkovic E, et al. A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies (abstract no. LB-231). Cancer Res. 2014;74:LB-231.
-
-
-
-
19
-
-
84927645044
-
Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies (abstract no. 5LBA)
-
Stathis A, Quesnel B, Amorim S, Thieblemont C, Zucca E, Raffoux E, et al. Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies (abstract no. 5LBA). Eur J Cancer. 2014;50:196.
-
(2014)
Eur J Cancer
, vol.50
, pp. 196
-
-
Stathis, A.1
Quesnel, B.2
Amorim, S.3
Thieblemont, C.4
Zucca, E.5
Raffoux, E.6
-
20
-
-
84930699565
-
Pharmacokinetic/pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
-
Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M. Pharmacokinetic/pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Invest New Drugs. 2014;32:985–94.
-
(2014)
Invest New Drugs
, vol.32
, pp. 985-994
-
-
Chalret du Rieu, Q.1
Fouliard, S.2
White-Koning, M.3
Kloos, I.4
Chatelut, E.5
Chenel, M.6
|